$9.7 billion major depressive disorder treatment market forecast to 2023

Product launches and patent expiries will push the major depressive disorder treatment market through a fluctuating growth period by 2023, a new report notes.

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide, according to a new report from PharmaPoint, saying that the MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD.

The therapeutics market for MDD will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products. According to the report, titled Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023, the MDD treatment market achieved sales of around $9.3 billion in 2013 across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a compound annual growth rate (CAGR) of 0.39%.